company background image
BMRN

BioMarin Pharmaceutical NasdaqGS:BMRN Stock Report

Last Price

US$117.27

Market Cap

US$21.8b

7D

5.9%

1Y

36.1%

Updated

29 Jan, 2023

Data

Company Financials +

BioMarin Pharmaceutical Inc.

NasdaqGS:BMRN Stock Report

Mkt Cap: US$21.8b

BMRN Stock Overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.

BMRN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance4/6
Financial Health4/6
Dividends0/6

My Notes

New

Notes are coming soon

BioMarin Pharmaceutical Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioMarin Pharmaceutical
Historical stock prices
Current Share PriceUS$117.27
52 Week HighUS$117.77
52 Week LowUS$70.73
Beta0.36
1 Month Change13.32%
3 Month Change35.37%
1 Year Change36.11%
3 Year Change40.44%
5 Year Change29.12%
Change since IPO793.49%

Recent News & Updates

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

Jan 09
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

Recent updates

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

Jan 09
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

May 25
Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

BioMarin Pharmaceutical (NASDAQ:BMRN) Has Debt But No Earnings; Should You Worry?

Feb 24
BioMarin Pharmaceutical (NASDAQ:BMRN) Has Debt But No Earnings; Should You Worry?

Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?

Oct 29
Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?

Are Investors Undervaluing BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) By 49%?

Sep 24
Are Investors Undervaluing BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) By 49%?

I Ran A Stock Scan For Earnings Growth And BioMarin Pharmaceutical (NASDAQ:BMRN) Passed With Ease

Aug 27
I Ran A Stock Scan For Earnings Growth And BioMarin Pharmaceutical (NASDAQ:BMRN) Passed With Ease

Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?

Jul 10
Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 19
BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) CEO Will Probably Find It Hard To See A Huge Raise This Year

A Look At The Fair Value Of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

May 03
A Look At The Fair Value Of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?

Apr 01
Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?

The BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price Has Gained 12% And Shareholders Are Hoping For More

Feb 17
The BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price Has Gained 12% And Shareholders Are Hoping For More

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 21% Discount?

Jan 22
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 21% Discount?

We're Not Counting On BioMarin Pharmaceutical (NASDAQ:BMRN) To Sustain Its Statutory Profitability

Dec 22
We're Not Counting On BioMarin Pharmaceutical (NASDAQ:BMRN) To Sustain Its Statutory Profitability

Shareholder Returns

BMRNUS BiotechsUS Market
7D5.9%0.8%2.8%
1Y36.1%7.1%-9.2%

Return vs Industry: BMRN exceeded the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: BMRN exceeded the US Market which returned -9.2% over the past year.

Price Volatility

Is BMRN's price volatile compared to industry and market?
BMRN volatility
BMRN Average Weekly Movement4.6%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: BMRN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: BMRN's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19963,045Jean-Jacques Bienaimehttps://www.biomarin.com

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.

BioMarin Pharmaceutical Inc. Fundamentals Summary

How do BioMarin Pharmaceutical's earnings and revenue compare to its market cap?
BMRN fundamental statistics
Market CapUS$21.79b
Earnings (TTM)US$83.91m
Revenue (TTM)US$2.01b

259.7x

P/E Ratio

10.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BMRN income statement (TTM)
RevenueUS$2.01b
Cost of RevenueUS$476.13m
Gross ProfitUS$1.53b
Other ExpensesUS$1.45b
EarningsUS$83.91m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.45
Gross Margin76.29%
Net Profit Margin4.18%
Debt/Equity Ratio23.7%

How did BMRN perform over the long term?

See historical performance and comparison